TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01149005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: novorapid / humalog short acting insulin
Description: 1-4 units will be injected Subcutaneously (SC), before every main meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novo Rapid Insulin (Novonordisk)
Description: Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
Study: NCT01926899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib administration
Study: NCT02519478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helmetless Tackling Training (HuTT)
Description: see previous sections
Study: NCT03697005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK single posterior crowns
Description: BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia-based single posterior crowns
Description: ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
Study: NCT02598856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) naloxone
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) naloxone
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) naloxone
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) naloxone
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) naloxone
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) naloxone
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) naloxone
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular (IM) naloxone
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
Study: NCT00676780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E (EGCG)
Description: 4 capsules daily with a meal for the duration of the study
Study: NCT02688140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT02180191

Intervention type: OTHER
Intervention: Comparison of the gut microbiota composition

Intervention type: OTHER
Intervention: Comparison of the gut microbiota composition
Study: NCT04647695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Description: a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
Study: NCT03714256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device, patient mobility, powered
Description: Pediatric mobility device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device, patient mobility, powered
Description: Pediatric mobility device
Study: NCT03231592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSA Group
Description: Already included in the arm descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Group
Description: Already included in the arm descriptions.
Study: NCT01132391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectogesic® (glyceryl trinitrate 0.4% ointment)
Description: 375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectogesic® (glyceryl trinitrate 0.4% ointment)
Description: 375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
Study: NCT01271595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham acupuncture
Description: 12 sessions of sham acupuncture over 8 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: 12 sessions of sham acupuncture over 8 weeks
Study: NCT02591251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine solution
Study: NCT02245308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patches
Description: Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile contingency management (mCM)
Description: Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine rescue method
Description: Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine rescue method
Description: Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
Study: NCT02407704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Study: NCT01503372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Oxaliplatin, Leukovorin (FLO)
Description: Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, Oxaliplatin, Leukovorin (FLO)
Description: Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
Study: NCT02407704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study: NCT02591251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline solution
Study: NCT05012709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multisensory stimulation therapy
Description: The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
Study: NCT02407704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
Study: NCT02337257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: subjects will receive one pill per day which contains 4000 IU/d for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects will receive placebo one pill per day for 16 weeks
Study: NCT00426907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unlimited postoperative weightbearing
Description: Unlimited postoperative weightbearing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unlimited postoperative weightbearing
Description: Unlimited postoperative weightbearing
Study: NCT01849224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic and lower extremity exercise
Study: NCT01936103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard group
Description: standard statin treatment:Atorvastatin statins 20mg / night .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive group
Description: intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
Study: NCT00312208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, doxorubicin, cyclophosphamide
Description: TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,doxorubicin, cyclophosphamide
Description: AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
Study: NCT03642366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries2 LiST Device + 5mg Tadalafil (1)
Description: Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries2 LiST Device + 5mg Tadalafil (2)
Description: Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham LiST Device + 5mg Tadalafil
Description: Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
Study: NCT01773993

Intervention type: DRUG
Intervention: Pregabalin
Description: The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
Study: NCT05340452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klaribact 125mg/5ml Suspension
Description: one single 20 mL dose (500mg) of the test drug will be administered to the volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid 125mg/5ml Suspension
Description: one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
Study: NCT01590446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN 111
Description: SC injection, Part 1 single dose and Part 2 multiple dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: SC injection, Part 1 single dose and Part 2 multiple dose
Study: NCT01373099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of a static, non-articulating cement spacer.
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of an articulating spacer.
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
Study: NCT04173481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rood's Group
Description: ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy.
Study: NCT01579058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisoprolol
Description: bisoprolol 5mg qd for 4 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 4 years
Study: NCT01709110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Administered orally
Study: NCT02789345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally
Study: NCT02189044

Intervention type: OTHER
Group type: OTHER
Intervention: Pilates Exercise
Description: The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall.
Study: NCT02774200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
Study: NCT04227275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN
Description: Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study: NCT00301392

Intervention type: OTHER
Group type: OTHER
Intervention: life-style intervention
Description: As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.

Intervention type: DRUG
Group type: OTHER
Intervention: Life style interventions plus concomitant use of pitavastatin.
Description: Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).